Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-12-15
2002-06-25
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C540S145000, C514S410000
Reexamination Certificate
active
06410568
ABSTRACT:
Photosensitizers are chemical light-sensitive compounds which undergo a photochemical reaction after the absorption of the light quantum. In the biological environment, they are accumulated by both malignant and some pre-malignant cells as a result of the metabolic processes in a higher concentration and also for a longer period than in healthy cells. The photosensitizers are activated by monochromatic laser light of appropriate wavelength and sufficient intensity. The photosensitizer is first excited by light absorption in a relatively short-lived singlet state which then changes into a more stable triplet state. This excited state can be subject to two different reactions.
It can react directly with a substrate and form radicals which form peroxides, hydroxyl radicals, superoxide anion radicals and other products after reaction with the oxygen (type I reaction) , or else transfer its energy to oxygen in its basic state and lead to the formation of singlet oxygen
1
O
2
(type II reaction). For most photosensitizers, an effect via a type II reaction is described. The singlet oxygen is highly reactive and can readily react oxidatively with biomolecules by lifting the ban on spinning (Henderson, B. W. and Dougherty, T. J., How does photodynamic therapy work?, Photochem. Photobiol., 1992, 55, 145-157).
Specific sites or types of cell destruction by PDT are not as yet precisely known. Depending on the type of photosensitizer in question and its charge, this accumulates in particular on cell membranes, in mitochrondria or lysosomes. Damage occurs to membranes through photooxidation of unsaturated fatty acids, lipid-peroxidation and protein-crosslinking (Gomer C. J., Rucker N., Ferrario A., Wong S., Properties and applications of photodynamic therapy, Radiat. Res., 1989, 120, 1-18).
The inhibition of certain membrane-positioned enzymes (Modica-Napoloitano J. S., Joxal J. L., Ara G., Oseroff A. R., Aprille J. R. Mitochrondial toxicity of cationic photosensitizers for phototherapy. Cancer Res., 1990, 50, 7876-7881), a change in the intracellular Ca
2+
-ion concentrations (Hubmer A., Hermann A., Überriegler K., Krammer B., Role of calcium in photodynamically induced cell damage of human fibroblasts, Photochem. Photobiol., 1996, 64, 211-215) and the induction of apoptosis (Luo Y., Chang C. K., Kessel D., Rapid initiation of apoptosis by photodynamic therapy, Photochem. Photobiol., 1996, 63, 528-534) are also discussed.
In medicine, this procedure is called photodynamic therapy (PDT) and is one of the most promising methods of treatment in oncology. PDT is used as the method of choice whenever the patients are either too old or too weak to cope with chemotherapeutic, surgical or radiological operations or when these have already failed. PDT can also be used together with and in addition to other tumor therapies and repeatedly on a patient, the effect being further increased by the synergy effects. The radiation periods are a few minutes, making it necessary to use cw lasers and waveguides for light transport.
Although PDT was already suggested as a method of therapy in 1990 by Raab (Raab O., Über die Wirkung fluoreszierender Stoffe auf Infusoria [The effect of fluorescent substances on infusoria], Z. Biol., 1900, 39, 524-526), significant advances were first achieved only in the 60s, when it was shown that hematoporphyrin derivatives (HPD) can be selectively accumulated in tumor tissue (Lipson R., Baldes E., Olson A., The use of a derivative of hematoporphyrin in tumor detection, J. Natn. Cancer Inst., 1961, 267, 1-8). Extensive tests have since been carried out with HPD (Kessel D. (ed.), Photodynamic Therapy of Neoplastic Disease, Vols. I and II. CRC Press, Boston 1990; Moan J., Porphyrin photosensitization and phototherapy, Photochem. Photobiol., 1986, 43, 681-690; Pass H. I., Photodynamic therapy in oncology: Mechanisms and clinical use, J. Natl. Cancer Inst., 1993, 85, 443-456). Treatment with Photofrin® is currently clinically approved in some countries for some indications.
On the basis of the promising clinical results obtained with Photofrin®, and because of various disadvantages of this substance (low absorption in the range from 700 to 900 nm, i.e. in a range in which the self-absorption of the tissue is minimal, chemical heterogeneity, high and enduring phototoxicity in daylight, inter alia), so-called photosensitizers of the second and third generations are increasingly being synthesized and tested. This group comprises numerous substance classes such as e.g. anthraquinones, anthrapyrazoles, perylene quinones, xanthenes, cyanines, acridines, phenoxazines and phenothiazines (Diwu Z. J. , Lown J. W. Phototherapeutic potential of alternative photosensitizers to porphyrins, Pharmac. Ther. , 1994, 63, 1-35). The photosensitizers of the third generation are selected according to the following criteria (Gomer C. J., Rucker N., Ferrario A., Wong S. Properties and applications of photodynamic therapy, Radiat. Res., 1989, 120, 1-18):
chemical purity
water solubility
minimal dark toxicity
significant absorption at wavelengths above 700 nm
high yields of singlet oxygen
predominant localisation in pathological tissue (e.g. tumor)
rapid secretion from normal tissue.
Currently, very intensive research is being carried out on the synthesis of bacteriochlorin derivatives. This is intended to very largely satisfy the above-listed selection criteria (Dougherty T. J. et al. WO 90/12573; Skalkos D. et al. WO 94/00118; Pandey R. K. et al. WO 95/32206; Dolphin D. et al. WO 96/13504; Pandey R. K. et al. WO 97/32885). Some of the newly synthesized bacteriochlorins have a negligible dark toxicity and a high tumor selectivity, are partially water soluble and have marked absorption bands in the range from 700 nm to 810 nm in the so-called “phototherapeutic window”. Thus they enable a treatment of tissue layers which lie deeper than 1 cm (Pandey R., Kozyrev A., Potter W. R., Henderson B. W., Bellnier T. J., Dougherty T. J., Long wavelength photosensitizers for photodynamic therapy, Photochem. Photobiol., 1996, 63, Abstracts of the 24
th
Annual Meeting of the American Soc. for Photobiology, TPM-E6).
Disadvantages of the known bacteriochlorin derivatives are:
a complicated and expensive synthesis process which usually necessitates a purification of the starting product,
their poor water solubility which, in the case of a systemic application, results in a dissolution in organic solvents and means an additional chemical burden on the organism,
their negative or neutral overall charge which rakes absorption by the cells difficult, as they are normally negatively charged,
chemical instability of the product.
The object of the present invention is to avoid the disadvantages named and to provide photosensitizers, the chemical and physical properties of which allow a technically and economically meaningful use.
This object is achieved by new porphyrins of the following general formula:
in which:
R
1
is C
1
to C
6
alkyl or aryl,
R
2
to R
5
independently of each other are H, OH, C
1
to C
6
alkyl, C
1
to C
6
alkylene or OR
6
, R
6
standing for C
1
to C
6
alkyl or aryl,
A
n−
is an anion and
n is 1 or 2.
The mono- or divalent anion is preferably selected from the group consisting of Cl
−
, Br
−
, I
−
,
SO
4
2−
.
In a particularly preferred version R
1
stands for a C
1
to C
6
alkyl group, i.e. methyl, ethyl, propyl, butyl, pentyl, hexyl, in particular methyl, the radicals R
2
to R
5
for H and the anion A
n−
for
TH new porphyrins can be prepared easily. Porphyrins of the following general structural formula serve as starting products:
in which R
2
to R
5
have the above meaning. These products are commercially available or can be easily synthesized from the compound customary in the trade, in which R
2
to R
5
stand for H.
The starting compounds are reacted with a compound of the general formula R
1
A in which R
1
and A have the above meaning.
In a preferred version of the process, methyltosylate,
is used as compound R
1
A.
The new c
Berr Frieder
Schastak Stanislaw
Shulga Alexander
Wiedemann Peter
Astrid Schastak
Crowell & Moring LLP
Habte Kahsay
LandOfFree
Porphyrins and their use as photosensitizer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Porphyrins and their use as photosensitizer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Porphyrins and their use as photosensitizer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2913815